A fresh and highly significant collaboration engineered by One Nucleus will further boost the international prospects of BioMedTech companies in the Cambridge UK cluster.
GW Pharmaceuticals, whose products are derived from cannabis, has earned an €11.9 million milestone payment.
Global Healthcare Exchange (GHX) – a Cambridge healthcare technology and services company – has continued its global expansion with another healthcare acquisition in Europe.
Lumora’s CEO, Dr Laurence Tisi is this year’s winner of the Commercial Innovator Prize, for the development of the BART (Bioluminescent Assay in Real Time) system, which detects infectious organisms including bacteria and viruses using luciferase – the same enzyme which lights up fireflies.
Cambridge SMEs and academics in the BioMedTech arena can pitch for a share of a £180 million UK government scheme designed to bridge the ‘valley of death’ for medical breakthroughs.
Cambridge BioMedTech cluster company BioGene is taking part in a £15 million-plus UK government initiative to fight sepsis – a potentially fatal illness caused by the body overreacting to an infection.
Lab21 in Cambridge is partnering a world-leading diagnostics company to find a fast detector for a fungus that can kill patients whose immune system is compromised.
Serial Cambridge entrepreneurs have spelt out the opportunities for the UK economy of leveraging the region’s life science excellence.
- Companies swarm to new Babraham bioincubator
- £2 million fund to bring patients in line
- Vernalis ready to flex its muscles
- Drug hunters alert to Cambridge startup
- AZ-Amgen boost for Cambridge
- BlueGnome strengthens US IVF team
- Günther in CEO saddle for Bicycle
- Avita Medical ramps up in US
- Healthcare at your fingertips in developing world
- Vernalis confirms AIM switch
- Pfizer ramps up Cambridge collaborations
- Horizon in global genetics initiative
Page 52 of 108